Search Results for keywords:"drug pricing and availability"

Search Results: keywords:"drug pricing and availability"

H. R. 1843 — To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
March 05, 2025
Status:Introduced in House
Congress:119
Words:829
H. R. 1843 proposes amendments to the Federal Food, Drug, and Cosmetic Act focused on increasing transparency in the applications for generic drugs. The bill requires the Secretary of Health and Human Services to inform drug manufacturers if their generic product is the same as the original...
Simple Explanation
H. R. 1843 wants to make it easier for people to know if a copy of a medicine is exactly like the original one, and it asks the people in charge to share all needed information and listen to what everyone has to say before making any big decisions.
H. R. 1051 — To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
February 06, 2025
Status:Introduced in House
Congress:119
Words:1,129
H.R. 1051 seeks to amend the Federal Food, Drug, and Cosmetic Act to address the approval process for generic drug applications. If the first applicant fails to start selling their drug within a set time, a later applicant could get approval under certain conditions, even if...
Simple Explanation
H.R. 1051 explains that if a company is too slow to sell a new medicine, another company might be allowed to start selling it instead, so people can get their medicines more quickly.

Showing 1 to 2 of 2 results